Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may detect that a first subscription, of a plurality of subscriptions associated with the UE, is associated with an active service on a first cellular network. The UE may search, for a second subscription of the plurality of subscriptions, for radio access technologies (RATs) and frequency bands that are compatible with a dual active mode of the UE. In some aspects, the UE may detect that the active service on the first cellular network has ended. Accordingly, the UE may search, for the second subscription, for RATs and frequency bands that are compatible with the dual active mode of the UE and for RATs and frequency bands that are incompatible with the dual active mode, before expiry of a timer associated with a power saving state. Numerous other aspects are described.

Abstract: Provided are ?-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers.

Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.

Abstract: Extended-release conjugates of stabilized GLP-1 agonists balance agonist stability with release rates to provide long lasting administration to treat diabetes and related conditions on once-a-month or less frequent dosing schedules.

Abstract: Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed.

Abstract: Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed.

Abstract: Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed.

Abstract: Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed.

Abstract: The present invention provides methods and compositions that permit controlled and prolonged drug release in vivo. The compounds are either prodrugs with tunable rates of release, or conjugates of the drug with macromolecules which exhibit tunable controlled rates of release.

Abstract: Leptomycin-type compounds according to formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.

Abstract: A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membranes impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.

Abstract: A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.

Abstract: Leptomycin-type compounds according to formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.

Abstract: Leptomycin-type compounds according to Formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.

Abstract: A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.

Abstract: Leptomycin-type compounds according to Formula I wherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.